<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="912">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05149274</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP14012107</org_study_id>
    <nct_id>NCT05149274</nct_id>
  </id_info>
  <brief_title>Evaluate the Pharmacokinetics and Safety of DWP14012 Tablet A and Compare Those of DWP14012 Tablet B in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-label Study to Evaluate the Pharmacokinetics and Safety of DWP14012 Tablet A and Compare Those of DWP14012 Tablet B in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pharmacokinetics (PK) and safety of oral DWP14012 tablet A will be evaluated and compared&#xD;
      with those of DWP14012 tablet B in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Actual">October 26, 2021</completion_date>
  <primary_completion_date type="Actual">October 26, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>(part 2) AUC last of DWP14012</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>(part 2) Cmax of DWP14012</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>(Part 2) AUC inf of DWP14012</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 2) Tmax of DWP14012</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Part 2) t1/2 of DWP14012</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(part 1-period 1) AUC last of DWP14012</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(part 1-period 1) Cmax of DWP14012</measure>
    <time_frame>0 (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(part 1- period 2) AUC last of DWP14012</measure>
    <time_frame>0 hours (pre-dose) on Day 5; 12 hours (pre-dose) on Day 7; 0 hours (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 (pre-dose), 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, 24, and 48 hours after dosing on Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(part 1- period 2) Cmax of DWP14012</measure>
    <time_frame>0 hours (pre-dose) on Day 5; 12 hours (pre-dose) on Day 7; 0 hours (pre-dose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 (pre-dose), 12.5, 13, 13.5, 14, 14.5, 15, 16, 18, 20, 24, and 48 hours after dosing on Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Phase 1 Study, Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DWP14012 Tablet A : single/multiple dose, 1 group, 2 period study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DWP14012 Tablet A 4T vs DWP14012 Tablet B 1T</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 Tablet A</intervention_name>
    <description>DWP14012 10mg</description>
    <arm_group_label>Part1</arm_group_label>
    <arm_group_label>Part2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DWP14012 Tablet B</intervention_name>
    <description>DWP14012 40mg</description>
    <arm_group_label>Part2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults &gt;=19years and &lt;=45 years of age&#xD;
&#xD;
          -  BMI &gt;=17.5 kg/m2 and &lt;30.5kg/m2, and body weight &gt;= 55kg for male and &gt;= 45kg for&#xD;
             femlae&#xD;
&#xD;
          -  subjects with no abnormal symptoms or findings based on physical examinations&#xD;
&#xD;
          -  subjects determined eligible based on the results of lab tests&#xD;
&#xD;
          -  subjects who agree to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with medical history that can not be participated&#xD;
&#xD;
          -  Subjects with results of lab tests performed at screening which meet any of the&#xD;
             following :&#xD;
&#xD;
               -  ALT or AST &gt; 1.5 times the upper limit of normal&#xD;
&#xD;
               -  Diagnosis of Helicobacter pylori (H. pylori) positive result&#xD;
&#xD;
          -  subject who is allergic to IP&#xD;
&#xD;
          -  subject with history of serious alcohol or drug abuse within 1 year prior to&#xD;
             screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Bundang CHA Medical Center</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

